Impact of Type 2 Diabetes Mellitus on Outcomes Following Transcatheter Aortic Valve Replacement: Insights From a Contemporary US Database.

Long‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort

Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V).

The impact of age and severity of comorbid illness on outcomes after isolated aortic valve replacement for aortic stenosis

of long-tErm prognostic siGnificance of coronary flow rEserve in special Disorders

Development of a Preoperative Transthoracic Echocardiography‐Based Nomogram for Predicting 1‐Year Cardiovascular Events in End‐Stage Renal Disease Kidney Transplant Recipients

Kidney transplantation (KT) is optimal therapy for end‐stage renal disease (ESRD), yet cardiovascular events (CVEs) are the top cause of morbidity and mortality in transplant recipients. We aimed to build a preoperative transthoracic echocardiography (TTE)‐based predictive model combined with clinical and laboratory in...

Comparison of Guideline‐Directed Medical Therapy in Black versus White Patients With Heart Failure With Reduced Ejection Fraction in a Large, Integrated Health Care System

Guideline‐directed medical therapy (GDMT) improves clinical outcomes for patients with heart failure with reduced ejection fraction (HFrEF). While GDMT treatment differences have been described for Black patients, data are limited.

Prospective Evaluation of Quality‐of‐Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION‐HF 12‐Month Results

Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium–glucose cotransporter‐2 (SGL...